Oncology Dominates As China Drug, Biologic Approvals Surge
Executive Summary
China saw a 150% increase in new drug approval applications in 2018, with oncology taking the lion's share of investigational new drug filings, notes a newly released annual report from China’s Center for Drug Evaluation. Meanwhile Darzalex has become the latest foreign drug to be approved.
You may also be interested in...
China's Hengrui Halts Most Generic Development
China’s favorite domestic drug maker seems to have a warning for the industry - innovate or halt. After the recent round of “4+7” centralized procurement saw some off-patent drugs priced at pennies, the leading Chinese firm Hengrui has decided to halve its generics portfolio to focus on innovative new drugs.
Hengrui Halts Most Generic Development After Prices Free Fall In China
China’s favorite domestic drug maker seems to have a warning for the industry - innovate or halt. After the recent round of “4+7” centralized procurement saw some off-patent drugs priced at pennies, the leading Chinese firm Hengrui has decided to halve its generics portfolio to focus on innovative new drugs.
Eisai's Halaven, GSK's Lupus Drug Among Latest China Approvals
GSK gains approval of first lupus drug in China, where Benlysta and Eisai’s breast cancer therapy Halaven also receive the green light.